Immunotherapy combination extends survival in advanced endometrial cancer
An immunotherapy-based regimen combining durvalumab and the PARP inhibitor olaparib demonstrated encouraging long-term survival outcomes for patients with advanced or recurrent endometrial cancer, according to new trial results presented by researchers from The University of Texas MD Anderson Cancer Center.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
